On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Rocket Pharmaceuticals stock can continue to show renewed price strength and clear that threshold.
See How IBD Helps You Make More Money In Stocks
Is Rocket Pharmaceuticals Stock A Buy?
Rocket Pharmaceuticals stock is trying to complete a consolidation with a 24.65 buy point. See if the biotech stock can break out in heavy trading. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech company showed 0% EPS growth in its most recent report. Sales gains came in at 0%. Rocket Pharmaceuticals is expected to report its latest results on or around Nov. 8.
Rocket Pharmaceuticals stock earns the No. 153 rank among its peers in the Medical-Biomed/Biotech industry group. HUTCHMED (China) ADR and Neurocrine Biosciences are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
